Evidence map›Paper›PMID 42362868›Full record

ArticleNature medicine2026

Re-administration of AAV-mediated gene therapy for OTOF-related deafness: a single-arm trial.

Xintai Fan, Longlong Zhang, Ziwen Gao, Lei Han, Ping Yang, Daqi Wang, Hongbing Yu, Qi Cao, Luoying Jiang, Xiaoyun Chen and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Xintai Fan *ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Longlong Zhang *ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Ziwen Gao *ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Lei Han *ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Ping YangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Daqi WangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Hongbing YuENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Qi CaoENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Luoying JiangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xiaoyun ChenENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-8141-4592
Xin ZhangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xiaoting ChengENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Liheng ChenENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Jiake ZhongENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0002-0915-1836
Jun LvENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Wei WangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Liling DaiENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Ziyi ZhouENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Linjie ShiENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Yuxin ChenENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Biyun ZhuENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0006-0608-5262
Shaowei HuENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Honghai TangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Zheng-Yi ChenEaton-Peabody Laboratories, Department of Otolaryngology-Head and Neck Surgery, Mass Eye & Ear/Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1452-4193
Wuqing WangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Bing ChenENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. bingchen@fudan.edu.cn.ORCID http://orcid.org/0000-0002-0988-9534
Huawei LiENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. hwli@shmu.edu.cn.ORCID http://orcid.org/0000-0001-5338-6910
Yilai ShuENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. yilai_shu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-8893-434X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82192864National Natural Science Foundation of China (National Science Foundation of China) 82225014National Natural Science Foundation of China (National Science Foundation of China) 82521001Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 23J31900100Shanghai Municipal Education Commission 2023ZKZD12
6 · The paper itself

Abstract

Re-administration of adeno-associated virus (AAV)-mediated gene therapy remains challenging due to neutralizing antibodies (NAbs) induced by the initial dose. We previously conducted a single-arm trial showing that single-dose administration of AAV-hOTOF gene therapy in individuals with OTOF-related deafness is safe and leads to hearing improvements. Here we initially demonstrate that AAV1-hOTOF re-administration to the contralateral ear in Otof

Indexed as

DeafnessDependovirusGenetic TherapyAnimalsAntibodies, NeutralizingChild, PreschoolFemaleGene Therapy AgentsGenetic VectorsHumansMaleMiceAntibodies, Neutralizing

Identifiers

PMID42362868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.